Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 17Lymphoma, Large B-Cell, Diffuse 12Lymphoma, Mantle-Cell 11Lymphoma 9Recurrence 5Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 5Multiple Myeloma 2Lymphoproliferative Disorders 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lymphatic Diseases 2Lung Neoplasms 2Leukemia 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Graft vs Host Disease 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurologic Manifestations 1Metastatic Pancreatic Adenocarcinoma 1Leukemia, Lymphoid 1Leukemia, B-Cell 1

Interventions

Rituximab 16Cyclophosphamide 16Peripheral Blood Stem Cell Transplantation 11fludarabine phosphate 10Cytarabine 9Methotrexate 8Vincristine 7blinatumomab 6Filgrastim 6Etoposide 6fludarabine 5Prednisone 5Mycophenolic Acid 5Lenalidomide 5Dexamethasone 5Cyclosporine 5merphos 4Whole-Body Irradiation 4Radiotherapy 4Ifosfamide 4Carboplatin 4venetoclax 3romidepsin 3prednylidene 3deltacortene 3Spinal Puncture 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Inotuzumab Ozogamicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Burkitt Lymphoma × ibrutinib × Clear all
NCT03223610 2026-06-05

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
155 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡